We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
+$26.5M
Cap. Flow %
0.97%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Miscellaneous 88.95%
2 Healthcare 8.73%
3 Energy 1.53%
4 Technology 0.21%
5 Industrials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERS icon
326
Cerus
CERS
$504M
– –
-100,000
Closed -$417K
CLLS
327
Cellectis
CLLS
$162M
– –
-22,700
Closed -$785K
CRDF icon
328
Cardiff Oncology
CRDF
$104M
– –
-208
Closed -$102K
CTSO icon
329
PUT
Cytosorbents Corp
CTSO
$19.1M
– –
-8
Closed -$222K
CYH icon
330
Community Health Systems
CYH
$419M
– –
-33,358
Closed -$1.5M
DHR icon
331
CALL
Danaher
DHR
$147B
– –
-1,488
Closed -$8.49M
DHR icon
332
Danaher
DHR
$147B
– –
-92,920
Closed -$5.3M
DHR icon
333
PUT
Danaher
DHR
$147B
– –
-1,488
Closed -$8.49M
ESPR
334
DELISTED
Esperion Therapeutics
ESPR
– –
-5,000
Closed -$489K
HALO icon
335
Halozyme
HALO
$12.1B
– –
-191,621
Closed -$3.37M
INCY icon
336
CALL
Incyte
INCY
$24.7B
– –
-201
Closed -$1.84M
INCY icon
337
PUT
Incyte
INCY
$24.7B
– –
-478
Closed -$4.38M
IONS icon
338
PUT
Ionis Pharmaceuticals
IONS
$7.85B
– –
-65
Closed -$414K
IWM icon
339
iShares Russell 2000 ETF
IWM
$76.9B
– –
-198,690
Closed -$24.7M
MDGL icon
340
Madrigal Pharmaceuticals
MDGL
$12.1B
– –
-11,400
Closed -$794K
LITS
341
CALL
Lite Strategy Inc
LITS
$37.1M
– –
-70
Closed -$252K
NVO
342
CALL
Novo Nordisk
NVO
$188B
– –
-8,444
Closed -$22.5M
OMER icon
343
PUT
Omeros
OMER
$1.24B
– –
-120
Closed -$264K
PBYI icon
344
Puma Biotechnology
PBYI
$477M
– –
-9,044
Closed -$1.64M
PFE icon
345
CALL
Pfizer
PFE
$157B
– –
-19,321
Closed -$63.8M
PFE icon
346
PUT
Pfizer
PFE
$157B
– –
-2,814
Closed -$9.29M
CNSY
347
PUT
Cerenome
CNSY
$16.1M
– –
0
– -$31K
RDHL
348
Redhill Biopharma
RDHL
$3.5M
– –
-108
Closed -$1.57M
RMTI icon
349
CALL
Rockwell Medical
RMTI
$31.6M
– –
-18
Closed -$2.19M
SNOA icon
350
Sonoma Pharmaceuticals
SNOA
$6.13M
– –
-465
Closed -$352K
12 13
14
15 16

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management's Q2 2015 filing shows 120 new, 93 increased, 80 reduced and 88 closed positions. Its largest new stake was ExxonMobil: 178,310 shares worth $14.8M. The largest sale was Tempest Therapeutics, an estimated $53.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Energy.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.